Wealth Enhancement Trust Services’s Janux Therapeutics JANX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$353	Buy	+23	New	+$333	﹤0.01%	1290

Other funds holding JANX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NNPTE

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Wealth Enhancement Trust Services's JANX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Janux Therapeutics (JANX) in Q2 2026: 23 shares worth $353. The stake represents ﹤0.01% of the portfolio and ranks #1290 among its holdings.

92 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Wealth Enhancement Trust Services held 23 shares of Janux Therapeutics worth $353 as of Q2 2026.
Janux Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Janux Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1290 holding.
92 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.